These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 1927767

  • 41. [MEC treatment (methotrexate, etoposide, cisplatin) for urothelial cancer].
    Miura T, Murai T, Shimura H, Kondo I.
    Gan To Kagaku Ryoho; 1992 May; 19(5):731-3. PubMed ID: 1580650
    [No Abstract] [Full Text] [Related]

  • 42. [A case of CA19-9 producing transitional cell carcinoma of the ureter effectively responsive to combination chemotherapy].
    Kanai S, Takagi Y.
    Hinyokika Kiyo; 1992 Nov; 38(11):1253-6. PubMed ID: 1485576
    [Abstract] [Full Text] [Related]

  • 43. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N.
    Cancer; 1989 Dec 15; 64(12):2448-58. PubMed ID: 2819654
    [Abstract] [Full Text] [Related]

  • 44. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results.
    Kuroiwa T, Naito S, Hasuo K, Kishikawa T, Masuda K, Kumazawa J.
    Cancer Chemother Pharmacol; 1995 Dec 15; 35(5):357-63. PubMed ID: 7850915
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Evaluation of chemotherapy in advanced urothelial carcinoma: with special reference to combination chemotherapy with adriamycin, cyclophosphamide and cisplatin (ACE chemotherapy)].
    Tobisu K, Matsumoto K, Takai K, Kakizoe T.
    Nihon Hinyokika Gakkai Zasshi; 1987 Feb 15; 78(2):327-34. PubMed ID: 3613336
    [No Abstract] [Full Text] [Related]

  • 48. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
    Igawa M, Kadena H, Ueda M, Usui T.
    Cancer Chemother Pharmacol; 1994 Feb 15; 35 Suppl():S1-4. PubMed ID: 7527732
    [Abstract] [Full Text] [Related]

  • 49. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K.
    Cancer Chemother Pharmacol; 1994 Feb 15; 35 Suppl():S5-8. PubMed ID: 7527735
    [Abstract] [Full Text] [Related]

  • 50. Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin).
    Lorusso V, Pagliarulo A, Selvaggi FP, Durini E, Riccardi F, Comella P, Fiorillo C, De Lena M.
    J Chemother; 1996 Apr 15; 8(2):154-8. PubMed ID: 8708748
    [Abstract] [Full Text] [Related]

  • 51. [Clinical evaluation of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin and cisplatin) for advanced urothelial cancer].
    Gohji K, Takenaka A, Goto A, Hara I, Matsumoto O, Kamidono S, Hamami G, Itani A, Harada K, Tadera N.
    Nihon Hinyokika Gakkai Zasshi; 1989 Mar 15; 80(3):321-8. PubMed ID: 2659869
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. CMV chemotherapy for advanced transitional cell carcinoma.
    Jeffery GM, Mead GM.
    Br J Cancer; 1992 Sep 15; 66(3):542-6. PubMed ID: 1520591
    [Abstract] [Full Text] [Related]

  • 54. [Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].
    Nishiyama T, Sasagawa T, Tanikawa T, Katayama Y, Kawakami Y, Tomita Y, Terunuma M, Kimura M, Sato S, Osawa T.
    Nihon Hinyokika Gakkai Zasshi; 1992 Mar 15; 83(3):352-7. PubMed ID: 1564837
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Carcinomatous meningitis from urothelial carcinoma of bladder and ureter: case report].
    Matsushita M, Kawasaki Y, Okada Y.
    Nihon Hinyokika Gakkai Zasshi; 2004 Nov 15; 95(7):817-9. PubMed ID: 15624493
    [Abstract] [Full Text] [Related]

  • 57. Results of adjuvant chemotherapy for invasive uroepithelial cancer.
    Uekado Y, Hirano A, Shinka T, Ohkawa T.
    Cancer Chemother Pharmacol; 1992 Nov 15; 30 Suppl():S55-8. PubMed ID: 1394819
    [Abstract] [Full Text] [Related]

  • 58. Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
    Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T.
    Br J Urol; 1995 Sep 15; 76(3):321-4. PubMed ID: 7551840
    [Abstract] [Full Text] [Related]

  • 59. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.
    Ueki O, Hisazumi H, Uchibayashi T, Naito K, Tajiri S, Takemae K, Kawaguchi K, Kameda K, Nishino A, Nango C.
    Cancer Chemother Pharmacol; 1992 Sep 15; 30 Suppl():S72-6. PubMed ID: 1394823
    [Abstract] [Full Text] [Related]

  • 60. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract.
    Hillcoat BL, Raghavan D, Matthews J, Kefford R, Yuen K, Woods R, Olver I, Bishop J, Pearson B, Coorey G.
    J Clin Oncol; 1989 Jun 15; 7(6):706-9. PubMed ID: 2654329
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.